Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$296.88 USD

296.88
2,410,872

+1.78 (0.60%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $296.81 -0.07 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Zacks Equity Research

Is Invesco Large Cap Value ETF (PWV) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PWV

Kanishka Das headshot

Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?

by Kanishka Das

Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.

Zacks Equity Research

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

by Zacks Equity Research

Sector ETF report for PJP

Zacks Equity Research

Is First Trust Dow 30 Equal Weight ETF (EDOW) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for EDOW

Zacks Equity Research

Amgen (AMGN) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

Amgen (AMGN) closed at $335.53 in the latest trading session, marking a +0.92% move from the prior day.

Zacks Equity Research

Exploring Analyst Estimates for Amgen (AMGN) Q2 Earnings, Beyond Revenue and EPS

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.

Zacks Equity Research

Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SCHD

Zacks Equity Research

Can Amgen (AMGN) Keep the Beat Streak Alive in Q2 Earnings?

by Zacks Equity Research

Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Zacks Equity Research

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Equity Research

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Zacks Equity Research

Amgen (AMGN) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

What Awaits Biogen (BIIB) in Q2 Earnings Post Leqembi Setback?

by Zacks Equity Research

Biogen's (BIIB) sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been hurt by increased competition.

Zacks Equity Research

Affimed (AFMD) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Affimed's (AFMD) second-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline candidates being developed for various cancer indications.

Zacks Equity Research

Amgen (AMGN) Advances But Underperforms Market: Key Facts

by Zacks Equity Research

In the closing of the recent trading day, Amgen (AMGN) stood at $334.85, denoting a +0.16% change from the preceding trading day.

Zacks Equity Research

Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Intellia's (NTLA) second-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.

Zacks Equity Research

Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Ginkgo's (DNA) total revenues are likely to have declined in the second quarter, owing to the expected ramp-down of the company's K-12 COVID testing services.

Zacks Equity Research

Amgen (AMGN) Stock Moves -0.39%: What You Should Know

by Zacks Equity Research

Amgen (AMGN) closed at $334.30 in the latest trading session, marking a -0.39% move from the prior day.

Zacks Equity Research

AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View

by Zacks Equity Research

AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of strong demand for its marketed products.

Sweta Killa headshot

What Lies in Store for Healthcare ETFs in Q2 Earnings?

by Sweta Killa

The healthcare sector has gained momentum lately on market rotation, with investors rushing to buy beaten-down stocks while shunning the hot technology sector.

Zacks Equity Research

Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?

by Zacks Equity Research

On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.

Zacks Equity Research

What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?

by Zacks Equity Research

Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release.

Zacks Equity Research

Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports second-quarter 2024 results.

Zacks Equity Research

Geron (GERN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Geron (GERN) is expected to primarily provide updates regarding the launch of its newly approved hematologic malignancy drug, Rytelo, in the United States when it reports second-quarter earnings.

Zacks Equity Research

Is a Beat in the Cards for CRISPR (CRSP) in Q2 Earnings?

by Zacks Equity Research

On CRISPR Therapeutics' (CRSP) second-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its newly approved gene therapy, Casgevy, and other pipeline updates.

Zacks Equity Research

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.